Zeiss Cirrus PathFinder Earns CE Mark for AI-Driven OCT Analysis

ZEISS Medical Technology has announced that its Cirrus PathFinder, a fully integrated AI-powered clinical support tool, has received the CE Mark. This milestone enables the launch of the technology in select European markets, further expanding ZEISS’s digital diagnostic capabilities in ophthalmology.

AI Integration Enhances OCT Interpretation and Efficiency

The Cirrus PathFinder is designed to improve clinical decision-making and streamline workflows through automated optical coherence tomography (OCT) interpretation. The tool utilizes proprietary deep learning algorithms to automatically detect abnormal macular OCT B-scans and is included as a licensed feature in the latest Cirrus software release.

The system offers AI-enhanced OCT angiography (OCTA) image quality, multi-layer segmentation, and automated scan analysis, allowing clinicians to manage large volumes of OCT data in real time. According to ZEISS, these capabilities enable faster, more focused reviews and support informed, data-driven decisions at the point of care.

“With PathFinder AI Decision Support, our game-changing technology identifies OCT B-scans that may require additional review, raising our advanced diagnostic portfolio to a new level of patient care support,” said Anuj Kalra, Head of Chronic Disease Management, ZEISS Medical Technology.

Key Functional Capabilities of Cirrus PathFinder

The Cirrus PathFinder supports several critical functions that enhance both diagnostic accuracy and operational efficiency. As part of the Cirrus ecosystem, it allows clinicians to perform high-throughput assessments without relying on external data exports or third-party platforms.

The AI-guided workflow flags areas of interest during image acquisition and prioritizes regions that may require detailed review. This enables the assessment of hundreds of scans simultaneously, improving the use of clinical time and enhancing patient care.

The new Cirrus software also delivers AI-powered visualization of vascular structures through improved OCTA imaging, including B-scan averaging and increased segmentation depth. This provides greater clarity and diagnostic precision across retinal layers.

In terms of infrastructure, enhanced connectivity and cybersecurity features are built into the update to meet evolving regulatory and compliance standards. The platform supports seamless review of legacy OCT data in combination with other diagnostic imaging modalities.